TRAWHIGH SIGNALFINANCIAL10-K

TRAW achieved profitability with a dramatic swing from -$166.5M to +$9.2M net income while significantly reducing total liabilities by 80%.

This represents a fundamental transformation in the company's financial position, moving from substantial losses to profitability alongside a major deleveraging event. The simultaneous reduction in cash reserves (-46.6%) and total assets (-57.5%) suggests either a significant debt paydown, asset divestiture, or corporate restructuring that has reshaped the balance sheet.

Comparing 2026-04-15 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

TRAW experienced a remarkable financial turnaround with revenue surging over 1000% to $2.8M and a $175.7M positive swing in net income to achieve profitability at $9.2M. The company dramatically reduced its financial obligations with total liabilities falling 80% from $56.6M to $11.2M, while stockholders' equity more than doubled to $11.6M. However, this restructuring came with a significant reduction in the company's asset base and cash position, with total assets declining 57.5% and cash reserves falling to $20.6M, suggesting either major debt repayment or a strategic divestiture that fundamentally altered the company's capital structure.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+1134.5%
$226K$2.8M

Strong top-line growth of 1134.5% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
+114.9%
$5.4M$11.6M

Equity base grew 114.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
+105.5%
-$166.5M$9.2M

Net income grew 105.5% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+87.4%
-$142.4M-$17.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
-80.1%
$56.6M$11.2M

Liabilities reduced 80.1% — deleveraging improves balance sheet strength and financial flexibility.

Current Assets
Balance Sheet
-68%
$25.0M$8.0M

Current assets declined 68% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-57.5%
$25.0M$10.6M

Total assets contracted 57.5% — asset sales, write-downs, or balance sheet optimization underway.

Interest Expense
P&L
-50%
$4K$2K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-46.6%
$38.5M$20.6M

Cash declined 46.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
+39%
-$29.8M-$18.2M

Operating cash flow surged 39% — exceptional cash generation, highest quality earnings signal.

LANGUAGE CHANGES
NEW — 2026-04-15
PRIOR — 2025-03-31
ADDED
The evaluated dose levels included 80, 120, 240, and 480 mg administered orally in capsule form.
The primary endpoints of the study were safety and tolerability; the secondary and other endpoints included determination of a drug pharmacokinetic profile.
The study enrolled healthy volunteers, adults 18-64 years old, into 4 cohorts.
Topline data showed good overall tolerability and a pharmacokinetic profile.
Sixteen AEs were recorded, of which three were possibly related to study drug during the study; all were mild headaches and resolved without treatment.
+7 more — sign up free →
REMOVED
The dose levels that were evaluated included 80, 120, 240, and 480 mg, taken once via oral capsules.
The primary endpoint of the study was the measurement of safety and tolerability, and the secondary and other endpoints included the determination of the drug pharmacokinetic profile.
Topline data showed good overall tolerability and a pharmacokinetic profile that appears to support the potential use of tivoxavir marboxil as a one-time treatment for influenza.
Sixteen AEs were recorded, of which three were reported as possibly related to study drug during the study; all were mild headaches.
Topline data from this study showed that a single dose of tivoxavir marboxil maintained plasma drug levels consistently above the EC90 and within the predicted therapeutic window for more than 23 days.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →